A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier

Nonmotor Symptoms in Subjects Without Evidence of Dopaminergic Deficits

(2015) Fabienne S. Sprenger et al.   MOVEMENT DISORDERS

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients

(2014) Marios Politis et al.   JOURNAL OF CLINICAL INVESTIGATION

Patients with scans without evidence of dopaminergic deficit: A long-term follow-up study

(2014) Amit Batla et al.   MOVEMENT DISORDERS

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

(2014) K. Marek et al.   NEUROLOGY

Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease

(2011) Ramachandiran Nandhagopal et al.   BRAIN

[18F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [18F]FDOPA and [11C]DASB PET study in Parkinson's disease

(2011) N. Pavese et al.   NEUROIMAGE

Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter

(2010) Karl Strecker et al.   JOURNAL OF NEUROLOGY

Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study

(2010) Marios Politis et al.   NEUROBIOLOGY OF DISEASE

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

(2008) A. Munoz et al.   BRAIN

Diagnostic Value of 123I-Ioflupane and 123I-Iodobenzamide SPECT Scans in 248 Patients with Parkinsonian Syndromes

(2008) Annemarie M.M. Vlaar et al.   EUROPEAN NEUROLOGY

Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study

(2008) R. Nandhagopal et al.   NEUROLOGY